Clinical Trials
13 trialsNCT04981509 2026-06-03
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01688973 2019-01-03
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00425386 2017-05-03
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00522249 2016-03-17
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
The Methodist Hospital Research Institute
Phase 1/2 Terminated
NCT01402089 2016-02-02
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Cantonal Hospital of St. Gallen
Phase 4 Completed
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00081614 2014-05-16
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00353301 2014-04-14
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 2 Completed
NCT00045487 2014-01-27
OSI-774
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT00060307 2013-02-28
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00193258 2013-01-31
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 1/2 Completed